DMOG (Synonyms: Dimethyloxallyl Glycine) |
Catalog No.GC16973
One-Click Copy Product Info
|
DMOG is a competitive and cell-permeable hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, as well as an activator of hypoxia-inducible factor-1α (HIF-1α).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 89464-63-1
Sample solution is provided at 25 µL, 10mM.
DMOG is a competitive and cell-permeable hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, as well as an activator of hypoxia-inducible factor-1α (HIF-1α)[1]. DMOG stabilizes HIF-1α and prevents its prolyl hydroxylation-mediated degradation by inhibiting HIF-PH enzymatic activity, thereby stabilizing HIF-1α and activating downstream target gene expression at both the cellular and animal levels[2]. DMOG is commonly used in research areas including HIF signaling pathway regulation, ischemia-reperfusion injury protection, angiogenesis, and neuroprotection[3,4].
In vitro, treatment of rat bone marrow mesenchymal stromal cells (BM-MSCs) with DMOG (500, 1000μM) for 72h significantly upregulated C-X-C chemokine receptor type 4 (CXCR4) protein expression compared with the control group[5]. DMOG (0.5mM) pretreatment of PC12 and HCT116 cells for 0.5h significantly inhibited mitochondrial respiration and activated glycolytic activity[6].
In vivo, Sprague-Dawley rats exposed to chronic hypoxia (10% O2) and treated with DMOG (100mg/kg; once daily; i.p.) for 4 weeks showed significant stabilization of myocardial HIF-1α protein levels[7]. In BALB/c mice pretreated with DMOG (8mg/mouse; i.p.) 2h prior to lipopolysaccharide (LPS)-induced endotoxic shock, DMOG significantly improved survival rate, decreased serum TNF-α levels, and increased IL-10 levels[8].
References:
[1] Zhang Y, Cai W, Ren Z, et al. Chiral supramolecular hydrogel loaded with dimethyloxalyglycine to accelerate chronic diabetic wound healing by promoting cell proliferation and angiogenesis[J]. Gels, 2022, 8(7): 437.
[2] Ding H, Gao Y S, Wang Y, et al. Dimethyloxaloylglycine increases the bone healing capacity of adipose-derived stem cells by promoting osteogenic differentiation and angiogenic potential[J]. Stem cells and development, 2014, 23(9): 990-1000.
[3] Sen T, Sen N. Treatment with an activator of hypoxia-inducible factor 1, DMOG provides neuroprotection after traumatic brain injury[J]. Neuropharmacology, 2016, 107: 79-88.
[4] Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation[J]. American Journal of Physiology-Heart and Circulatory Physiology, 2005, 289(2): H542-H548.
[5] Yinfei W, Aiping J, Chao F, et al. DFO and DMOG up-regulate the expression of CXCR4 in bone marrow mesenchymal stromal cells[J]. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 2013, 68(10): 835-838.
[6] Zhdanov A V. HIF-independent inhibition of mitochondrial function by DMOG: Immediate–early effects and long-term consequences[J]. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 2014.
[7] Zhang S, Ma K, Liu Y, et al. Stabilization of Hypoxia-inducible Factor by DMOG Inhibits Development of Chronic Hypoxia–Induced Right Ventricular Remodeling[J]. Journal of cardiovascular pharmacology, 2016, 67(1): 68-75.
[8] Hams E, Saunders S P, Cummins E P, et al. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells[J]. Shock, 2011, 36(3): 295-302.
| Cell experiment [1]: | |
|
Cell lines |
BM-MSCs |
|
Preparation Method |
BM-MSCs were treated with DMOG (500, 1000μM) for 72h, then cells were collected and subjected to Western blot analysis using anti-CXCR4 antibodies. |
|
Reaction Conditions |
500, 1000μM; 72h |
|
Applications |
Treatment wtih DMOG significantly upregulated CXCR4 protein expression levels in BM-MSCs. |
| Animal experiment [2]: | |
|
Animal models |
BALB/c mice |
|
Preparation Method |
BALB/c mice were pretreated with DMOG (8mg/mouse; i.p.) for 2h, followed by LPS (10mg/kg; i.p.) injection to induce endotoxic shock. Survival was monitored, and serum levels of TNF-α and IL-10 were measured at 3h after LPS treatment by MSD multiplex cytokine array and ELISA, respectively. |
|
Dosage form |
8mg/mouse; i.p. |
|
Applications |
Treatment with DMOG significantly improved the survival rate of mice with endotoxin shock, reduced serum TNF-α, and increased IL-10 levels. |
References: [1] Yinfei W, Aiping J, Chao F, et al. DFO and DMOG up-regulate the expression of CXCR4 in bone marrow mesenchymal stromal cells[J]. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 2013, 68(10): 835-838. [2] Hams E, Saunders S P, Cummins E P, et al. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells[J]. Shock, 2011, 36(3): 295-302. | |
| Cas No. | 89464-63-1 | SDF | |
| Synonyms | Dimethyloxallyl Glycine | ||
| Chemical Name | methyl 2-[(2-methoxy-2-oxoethyl)amino]-2-oxoacetate | ||
| Canonical SMILES | COC(=O)CNC(=O)C(=O)OC | ||
| Formula | C6H9NO5 | M.Wt | 175.14 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7097 mL | 28.5486 mL | 57.0972 mL |
| 5 mM | 1.1419 mL | 5.7097 mL | 11.4194 mL |
| 10 mM | 571 μL | 2.8549 mL | 5.7097 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)